Oculus Innovative Sciences Appoints Jerry McLaughlin to Its Board of Directors

Oculus Innovative Sciences Appoints Jerry McLaughlin to Its Board of Directors

PETALUMA, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS) announced today the appointment of John G.
(Jerry) McLaughlin to its board of directors. In this role, he will also serve
as a non-chairperson member to the company's audit committee and chair of the
nominating and corporate governance committee.

McLaughlin has served as interim CEO of Applied BioCode, Inc., an emerging
molecular diagnostic company, since November 2011. He also founded and
currently serves as president and CEO of DataStream Medical Imaging Systems,
Inc., which develops diagnostic imaging software applications that work in
conjunction with existing digital radiology platforms. He previously served as
president of DataFlow Information Systems, from July 2007 to December 2011,
and president and CEO of CompuMed, Inc. from May 2002 to June 2007.

Previously, McLaughlin served in senior level marketing and salespositions at
healthcare companies: Diagnostic Products Corporation (acquired by Siemens),
UniPath (medical division of Unilever) and Boehringer MannheimDiagnostics.

"We are pleased to add as our first new Oculus board member a sales and
commercial expert," stated Jim Schutz, CEOof Oculus. "Jerry brings an
extensive sales background in drugs, devices anddiagnostics, in the United
Statesand internationally, which is highly relevant as we lay the ground work
for our continued commercialization efforts while concurrently spinning off
ourdrug subsidiary, Ruthigen."

About Oculus Innovative Sciences

Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) is a commercial healthcare
company that designs, produces and markets innovative, safe and effective
drugs, devices and nutritional products. Oculus is pioneering innovative
solutions in multiple markets for the dermatology, surgical, wound care and
animal healthcare markets, and has commercialized products in the United
States, Europe, India, China, Mexico and select Middle East countries. The
company's headquarters are in Petaluma, California, with manufacturing
operations in the United States and Latin America. More information can be
found at www.oculusis.com.

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "serve," "spinning off" and"continued,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.

Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.

CONTACT: Media and Investor Contact:
         Oculus Innovative Sciences, Inc.
         Dan McFadden
         Director of Public and Investor Relations
         (425) 753-2105
         dmcfadden@oculusis.com